| Popis: |
Objective: To investigate the clinical characteristics and prognosis of patients with primary bone diffuse large B-cell lymphoma.The clinical data of 15 patients with primary diffuse large B-cell lymphoma treated in our hospital from January 2013 to December 2020 were collected, the clinical data and prognosis of the patients were analyzed retrospectively.The median age of the 15 patients was 59 (19-89) years old; among the patients, 7 were males and 8 were females, ostealgia was the initial symptom. The pathological types of the 15 patients were diffuse large B-cell lymphoma (DLBCL), 5 cases of Has type GCB subtype (5/15), and 10 cases of Non-GCB subtype (10/15). After 15 patients were diagnosed, 11 patients (11/15) received chemotherapy, 3 patients (3/15) received surgery, and 1 patient was untreated (1/15), median chemotherapy courses was 5 (1-9). 8 patients have achieved complete remission (8/15), 3 patients achieved partial remission (3/15), and 1 patient achieved stable disease (1/15), 1 patient was lost to follow-up (1/15), 1 patient was untreated (1/15), and 1 patient was progression of disease (1/15). Age, pathological subtype, sex, stage, β2-MG level, LDH level, and the using of rituximab were not correlated with the complete remission rate of the patients(P0.05), while the IPI score was correlated with the recent complete remission rate (P0.05). The median follow-up time was 19 (1-38) months, 10 patients survived, in which 6 cases were still in complete remission, and the median time to progression-free survival was 15 (1-38) months.The first symptom of primary bone diffuse large B-cell lymphoma is bone pain, the main pathological subtype is Non-GCB, the optimal treatment is combined chemotherapy, and the IPI score is related to the prognosis of the treatment.原发骨弥漫大B细胞淋巴瘤患者的临床特征及预后分析.探讨原发骨弥漫大B细胞淋巴瘤患者的临床特点及其预后.收集甘肃省人民医院2013年1月至2020年12月收治的15例原发骨弥漫大B细胞淋巴瘤患者的临床资料，并对其临床特点及预后进行回顾性分析和总结.15例患者的中位发病年龄为59（19-89）岁；男性7例，女性8例，首发症状均为骨痛； 15例患者病理类型均为弥漫大B细胞淋巴瘤(DLBCL)，Has分型GCB亚型5例（5/15），Non-GCB亚型10例（10/15）。15例患者中，11例（11/15）患者接受化疗，3例（3/15）患者接受手术治疗，1例患者未治疗（1/15），中位接受化疗疗程数为5（1-9）疗程。评估近期疗效，8例患者达CR（8/15）,3例达PR（3/15），1例SD（1/15）,1例失访（1/15），1例未治疗（1/15），1例PD（1/15）。年龄、病理亚型、性别、分期、β2-MG 水平、LDH 水平、是否应用利妥昔单抗与完全缓解率均无统计学相关性（P＞0.05），IPI评分与近期完全缓解率相关（P＜0.05）。中位随访时间19(1－38)个月，10例存活，其中6例仍完全缓解，中位无进展生存时间为15(1－38)个月.原发骨弥漫大B细胞淋巴瘤首发症状以骨痛为主，病理亚型以Non-GCB为主，治疗以联合化疗为主， IPI评分与治疗预后相关. |
